Hims & Hers Health said it completed its acquisition of Eucalyptus, adding a business that has served more than 850,000 customers as of May 2026 and expanding the company’s footprint across Australia, Canada, Germany, Japan and the United Kingdom.
The deal gives Hims & Hers a broader international reach on top of its earlier acquisitions of Zava and Livewell. The company said it now has a leading presence in the U.S., U.K., Australian and Canadian markets, with a growing presence in France, Germany, Ireland, Spain and Japan.
Management said the enlarged platform can now reach hundreds of millions of people across four continents. The company tied the expanded scale to its long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
The acquisition also adds to Hims & Hers’ clinical and operational footprint. Eucalyptus brings local regulatory expertise and a customer base built through digital health programs in multiple markets, while Hims & Hers said the combination should deepen its data pool and network effects globally.
Chief Executive Andrew Dudum said the acquisition gives the company a foundation to become an “everyday health companion” for consumers worldwide. Tim Doyle, now senior vice president of international at Hims & Hers and formerly chief executive of Eucalyptus, said the deal allows the teams in Australia, Canada, Germany, Japan and the U.K. to build on what they have already developed and expand to more customers. As a result of these announcements, the company's shares have moved 6.81% on the market, and are now trading at a price of $27.93. Check out the company's full 8-K submission here.
